Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1316Neoplasms 1104Carcinoma, Non-Small-Cell Lung 916Prostatic Neoplasms 747Colorectal Neoplasms 645Lung Neoplasms 621Neoplasm Metastasis 470Multiple Myeloma 444Leukemia, Myeloid, Acute 440Pancreatic Neoplasms 392Ovarian Neoplasms 388Melanoma 346Carcinoma, Hepatocellular 308Brain Neoplasms 290Squamous Cell Carcinoma of Head and Neck 285Recurrence 285Glioblastoma 260Stomach Neoplasms 252Head and Neck Neoplasms 250Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Carcinoma, Renal Cell 237Lymphoma 235Triple Negative Breast Neoplasms 233Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Hematologic Neoplasms 216Urinary Bladder Neoplasms 212Lymphoma, Non-Hodgkin 203Glioma 202Sarcoma 200

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Recurrent Skin Squamous Cell Carcinoma × 90 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡